Natera Stock Surges 10.74% After Japan Approves Signatera Cancer Detection Test
Following regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Natera announced its Signatera test has been approved to support adjuvant treatment in colorectal cancer (CRC) patients. The stock surged 10.74%, marking its largest single-day gain since
NTRA1.17%
GateNews·06-24 22:34
